Clinical Trial Update: A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EXT608 for safety, tolerability and efficacy in adults with hypoparathyroidism is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• EXT608

Snippet

Sponsor: Extend Biosciences Inc. | Conditions: Hypoparathyroidism | Phase 2 | Status: RECRUITING